Evidence map›Paper›PMID 39828690›Full record

ArticleJournal of nanobiotechnology2025

Enhancing hepatocellular carcinoma therapy with DOX-loaded SiO

Huanyu Chen, Jun Liu, Zhichao Cao, Jiajia Li, Hong Zhang, Qianqian Yang, Jian Cheng, Yuxian Shen, Kewu He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huanyu Chen *Imaging Center, The Third Affiliated Hospital of Anhui Medical University, Hefei, 230061, China.
Jun Liu *School of Basic Medical Sciences and Biopharmaceutical Research Institute, Anhui Medical University, Hefei, 230032, China.
Zhichao CaoImaging Center, The Third Affiliated Hospital of Anhui Medical University, Hefei, 230061, China.
Jiajia LiCentral Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Hong ZhangImaging Center, The Third Affiliated Hospital of Anhui Medical University, Hefei, 230061, China.
Qianqian YangImaging Center, The Third Affiliated Hospital of Anhui Medical University, Hefei, 230061, China.
Jian ChengSuzhou Institute for Advanced Research, University of Science and Technology of China, Suzhou, 215123, China. cjivn@ustc.edu.cn.
Yuxian ShenSchool of Basic Medical Sciences and Biopharmaceutical Research Institute, Anhui Medical University, Hefei, 230032, China. shenyx@ahmu.edu.cn.
Kewu HeImaging Center, The Third Affiliated Hospital of Anhui Medical University, Hefei, 230061, China. hekewu@ahmu.edu.cn.

Funding

Basic and Clinical Improvement Project of the Third Affiliated Hospital of Anhui Medical University 2022sfy002Key project of Regional Innovation and Development Joint Fund of National Natural Science Foundation U21A20345Key Research and Development Project of Anhui Province 2023s07020023
6 · The paper itself

Abstract

Chemotherapeutic drugs often fail to provide long-term efficacy due to their lack of specificity and high toxicity. To enhance the biosafety and reduce the side effects of these drugs, various nanocarrier delivery systems have been developed. In this study, we loaded the anticancer drug doxorubicin (DOX) and an MRI contrast agent into silica nanoparticles, coating them with pH-responsive and tumor cell-targeting polymers. These polymers enable the carrier to achieve targeted delivery and controlled drug release in acidic environments. This integrated diagnostic and therapeutic strategy successfully achieved both the diagnosis and treatment of liver cancer. Additionally, we demonstrated that the nanocarrier inhibits autophagic flux in liver cancer cells by targeting the autophagy-lysosome pathway and regulating the nuclear translocation of TFEB, thereby promoting tumor cell death. This novel diagnostic-integrated nanocarrier is expected to be a promising tool for targeted liver cancer treatment.

Indexed as

AutophagyBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCarcinoma, HepatocellularDoxorubicinLiver NeoplasmsNanoparticlesSilicon DioxideTOR Serine-Threonine KinasesAnimalsAntineoplastic AgentsCell Line, TumorDrug CarriersDrug LiberationHep G2 CellsHumansMiceAntineoplastic AgentsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsDoxorubicinDrug CarriersMTOR protein, humanSilicon DioxideTFEB protein, humanTOR Serine-Threonine KinasesAutophagic fluxHepatocellular carcinomaLysosomeMRI imagingNanodrug

Identifiers

PMID39828690
PMCPMC11743218

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.